Clinical trials: Ascites, Malignant
Liver Cirrhoses, Malignant Ascites
International Alfapump Cohort Study
This Registry is designed to follow patients who have been implanted with an alfapump system, which is a newly marketed product from Sequana Medical AG, a Swiss Medical Device company.
- Trial name
- TOPMOST (NCT04326946)
- Testing
- Alfapump
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 400 people
- Sponsor
- Sequana Medical N.V.
Gastric Cancer, Pancreatic Cancer
GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites
Phase I Part : Confirm the safety of GAIA-102 as a monotherapy or GAIA-102 and pembrolizumab in combination for advanced gastrointestinal cancer of microsatellite stable with malignant ascites, and determine the recommended…
- Trial name
- NCT05438459
- Testing
- GAIA-102, Pembrolizumab, Trifluridine/tipiracil hydrochloride (FTD/TPI)
- Where
- Japan
- Volunteers
- 176 people
- Sponsor
- Kyushu University
Peritoneal Carcinomatosis, Peritoneal Metastases
CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)
This is an open-label, dose-escalation, phase I trial of the safety and efficacy of anti-CEA intraperitoneal CAR-T infusions for treatment in patients with CEA-expressing adenocarcinoma peritoneal metastases or malignant ascites.
- Conditions
- Peritoneal Carcinomatosis, Peritoneal Metastases, Colorectal Cancer, Gastric Cancer
- Trial name
- NCT03682744
- Testing
- anti-CEA CAR-T cells
- Where
- 2 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sorrento Therapeutics, Inc.
Gastric Cancer
A Real-world Research on the Prevention and Treatment of Peritoneal Metastasis and Malignant Ascites by Intraperitoneal Infusion of rmhTNF in Gastric and Colorectal Malignant Tumors
Peritoneal metastasis is the main factor leading to poor prognosis in patients with gastric cancer or colorectal cancer. Although current systemic treatment regimens can prolong the time to peritoneal metastasis, the long-term…
- Trial name
- NCT06496919
- Testing
- Recombinant Mutant Human Tumor Necrosis Factor
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Wuhan University
Refractory Malignant Ascites
Phase I Trial of Intraperitoneal Bevacizumab in Refractory Malignant Ascites
Malignant ascites often has a profound impact on the quality of life of cancer patients. Current treatments,including dietary, medical, and procedural are often temporary and unsatisfactory options in patients approaching the end…
- Trial name
- NCT01852409
- Testing
- bevacizumab
- Where
- 2 sites in China
- Volunteers
- 18 people
- Sponsor
- Peking University
Malignant Ascites
Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard Therapy
This study is a prospective, multi-cohort Phase Ib/II clinical trial, consisting of two stages as follows: 1. Phase Ib Dose-Escalation Stage To explore the dose-limiting toxicities (DLT) of intraperitoneally administered…
- Trial name
- NCT07397819
- Testing
- liposomal irinotecan monotherapy, Liposomal Irinotecan + rmhTNF-NC, Liposomal Irinotecan + Bevacizumab
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Dong sheng Zhang
Malignant Ascites, Cancer
A Study of M701 (EpCAM and CD3) in Malignant Ascites
This study is to investigate the safety, tolerability, PK, PD and immunogenicity of multiple ascending doses of M701 administered intraperitoneally to patients with malignant ascites caused by advanced solid tumors.
- Trial name
- NCT04501744
- Testing
- Cohort 1 of M701, Cohort 2 of M701, Cohort 3 of M701
- Where
- 2 sites in China
- Volunteers
- 35 people
- Sponsor
- Wuhan YZY Biopharma Co., Ltd.
Ascites
Trial of Sunitinib for Refractory Malignant Ascites
The study is to see whether treatment with Sunitinib decreases the accumulation of ascites in patients with refractory malignant ascites.
- Trial name
- NCT00796861
- Testing
- Sunitinib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Milton S. Hershey Medical Center
Malignant Ascites
Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Ascites
1. The safety and tolerability of single-dose of SCB-313 will be evaluated by intraperitoneal injection; 2. The safety and tolerability of repeated-dose of SCB-313 will be evaluated by intraperitoneal injection once a day for 3…
- Trial name
- NCT04051112
- Testing
- SCB-313
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Sichuan Clover Biopharmaceuticals, Inc.
Ovarian Cancer With Malignant Ascites
Clinical Study in Treatment of Malignant Ascites of Ovarian Cancer With Intraperitoneal Injection Bevacizumab Combined With Intraperitoneal Hyperthermic Perfusion Chemotherapy
To study the efficacy and safety of intraperitoneal injection bevacizumab combined with intraperitoneal hyperthermic perfusion chemotherapy in treatment of malignant ascites of ovarian cancer.
- Trial name
- NCT01838538
- Testing
- Bevacizumab, TC:paclitaxel + carboplatin
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Chinese PLA General Hospital
Pleural Effusion, Malignant
IFN-γ Combined With T Cells in the Treatment of Refractory Malignant Pleural Effusion and Ascites
The purpose of this study was to evaluate the efficacy of IFN- Y combined with T cells in the treatment of refractory malignant pleural effusion and acties, using a multicenter, single-arm, open design.
- Trial name
- NCT05268172
- Testing
- IFN-γ and CIK cells, Tcm cells or CAR T cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Affiliated Hospital of Jiangnan University
Pleural Effusion, Ascites
Investigating Signal Change in Malignant and Non-malignant Pleural Effusions and asCitic Fluid Using fTiR Analysis
Lung cancer is a common cancer, associated with a high mortality rate. Pleural effusions are common in lung cancer, developing in up to 40% of patients.
- Trial name
- SPECTRA (NCT04533854)
- Where
- United Kingdom
- Volunteers
- 137 people
- Sponsor
- Portsmouth Hospitals NHS Trust
Malignant Ascites
A Study of Bevacizumab to Prevent Malignant Ascites
The purpose of this study is to determine the effectiveness of using Bevacizumab in the prevention of recurrent malignant ascites. Ascites is a debilitating and unpleasant complication of several types of cancer.
- Trial name
- NCT00908219
- Testing
- Bevacizumab
- Where
- 3 sites in United States
- Sponsor
- Baylor College of Medicine
Malignant Ascites
A Phase I Study of SIM0388 in Participants With Malignant Ascites.
Malignant Ascites is a common complication of malignant tumor. The objective of this study is to evaluate the safety, efficacy, and pharmacokinetic characteristics of intraperitoneal perfusion with Docetaxel Polymeric Micelles…
- Trial name
- SIM0388-101 (NCT07007988)
- Testing
- SIM0388
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Malignant Ascites
The Efficacy of Bevacizumab and Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rmhTNF-NC) in the Treatment of Malignant Ascites
1. More than half of peritoneal metastases are from digestive tract. Peritoneal metastasis has poor prognosis, poor treatment response and limited means. 2.
- Trial name
- NCT06433869
- Testing
- serplulimab, Bevacizumab, rmhTNF-NC
- Where
- 3 sites in China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-sen University
Solid Tumor, Malignant Ascites
SK-NK Injection in Patients With Advanced Solid Tumors Accompanied by Malignant Ascites
This study is divided into two phases. Patients with recurrent or metastatic solid tumors accompanied by malignant ascites who have failed previous standard treatments are enrolled.
- Trial name
- NCT06991478
- Testing
- SK-NK injection
- Volunteers
- 10 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Digestive System Neoplasms
IP rmhTNF-NC + Tislelizumab + Palliat RT for GIT Tumor Malignant Ascites After Failed Std Tx
This study is a prospective, non-randomized, dual-cohort Phase II clinical trial designed to explore the efficacy and safety of radiotherapy combined with intraperitoneal injection of Recombinant Mutant Human Tumor Necrosis…
- Trial name
- NCT07196540
- Testing
- Radiotherapy for large-volume abdominal lesions + whole peritoneal cavity low-dose radiotherapy + rmhTNF-NC + tislelizumab
- Volunteers
- 78 people
- Sponsor
- Sun Yat-sen University
Malignant Pleural Effusion, Malignant Peritoneal Effusion
Safety and Efficacy Study of Virus Activated Killer Immune Cells (VAK) for Malignant Pleural and Peritoneal Effusion
Theory of VAK： 1. Immune cells (T cells for example) of cancer subjects may be domesticated by the tumor microenvironment, and have low efficacy to kill cancer cells.
- Trial name
- NCT05565014
- Testing
- Virus Activated Killer immune Cells, Saline
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Sheng Hu
Malignant Pleural Effusion, Malignant Ascites
Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer
The purpose of this study to find out if tocilizumab can be safely infused into chest or abdominal cavities of patients with malignancy ascites (MA) or malignant pleural effusions (MPE).
- Trial name
- RIOT2 (NCT06016179)
- Testing
- Tocilizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Malignant Ascites, Colorectal Adenocarcinoma
TLR9 Immunotherapy for Peritoneal Carcinomatosis
The goal of this clinical trial is to determine the safety and efficacy of of ACM-CpG for inoperable peritoneal metastases or malignant ascites.
- Conditions
- Malignant Ascites, Colorectal Adenocarcinoma, Peritoneal (Metastatic) Cancer, Appendiceal Adenocarcinoma
- Trial name
- TIPC (NCT07658196)
- Testing
- ACM-CpG
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Brown University